Abilify MyCite
The news comes months after reports that the company had furloughed staff and couldn't secure additional funding for its-ingestible sensor business.
The pharma company walks away with the full license for Proteus' mental health treatment adherence technology.
The digital pill maker's employees were brought back after the company secured $5 million in emergency funding, but CNBC's report suggests that several are now looking elsewhere for work.
As the Abilify MyCite platform nears a full rollout, the companies said they are looking forward to employing the technology toward additional mental health therapies.
The two companies are planning a limited initial deployment to gather additional real-world data before a wider release.